Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + codeine is a fixed-dose combination analgesic containing the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the opioid analgesic codeine. Ibuprofen acts primarily by inhibiting cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which leads to decreased inflammation, pain, and fever. Codeine is a weak opioid that exerts its effect mainly through partial metabolic conversion to morphine; it binds to mu-opioid receptors in the central nervous system, altering pain perception and response. The combination provides additive or synergistic pain relief for acute moderate pain when other non-opioid options are insufficient[3][5][10]. It is used for short-term management of mild to moderate pain such as postoperative or dental pain[3][5]. The efficacy of this combination has been demonstrated in clinical studies, though some evidence suggests it may not always be superior to ibuprofen alone[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + codeine.